In a recent interview, Kasim Kutay, Chief Executive Officer of Novo Holdings, announced the company’s ambitious plans for further acquisitions and investments, particularly in Asia.
As the main owner of Novo Nordisk A/S NVO, Novo Holdings, holding 77% of the votes, is gearing up for an active role in dealmaking.
Kutay emphasized the need to scale up and strategically utilize the dividends from Novo Nordisk’s highly successful medicines for obesity and diabetes.
A comprehensive U.S. study revealed that the use of Novo Nordisk A/S’s NVO drugs Ozempic and Wegovy, widely prescribed for type 2 diabetes and obesity, respectively, is not associated with an increased risk of suicidal thoughts.
The company envisions significant investment opportunities in Asia, driven by the expanding middle class, pushing countries like India.
However, Kutay acknowledged the challenges ahead, Bloomberg noted, citing uncertainties related to interest rates and geopolitics that could make 2024 a particularly demanding year for investors.
According to data by 46brooklyn Research, commissioned by the Wall Street Journal, the price for Novo Nordisk’s Ozempic was increased at the start of the year by 3.5% to nearly $970 for a month’s supply.
Novo Holdings, owned by the philanthropic Novo Nordisk Foundation, manages assets totaling DKK 805 billion ($117 billion) as of the end of 2022.
With the company’s annual payout projected to nearly double from the previous year, Novo Holdings is poised for considerable financial strength in the coming months.
As Kutay put it, “We anticipate doing a fair amount more in 2024 and indeed going forward because the cash flows that are coming our way are obviously going to be quite significant.”
Read Next: Weight-Loss Drug Boom: Philanthropy Powerhouse Emerges As Lilly Endowment Comes Closer To Gates Foundation.
Price Action: NVO shares are down 0.33% at $107.19 during the premarket session on the last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
